Combining artificial intelligence with next-generation sequencing technologies offers unprecedented possibilities for dynamic genomic analyses to better understand polygenic cardiovascular diseases.
The integration of artificial intelligence with genomic and clinical data holds promise for advancing personalized medicine in polygenic cardiovascular diseases.
Polygenic diseases, which are genetic disorders caused by the combined action of multiple genes, pose unique and significant challenges for the diagnosis and management of affected patients. A major goal of cardiovascular medicine has been to understand how genetic variation leads to the clinical heterogeneity seen in polygenic cardiovascular diseases (CVDs). Recent advances and emerging technologies in artificial intelligence (AI), coupled with the ever-increasing availability of next generation sequencing (NGS) technologies, now provide researchers with unprecedented possibilities for dynamic and complex biological genomic analyses. Combining these technologies may lead to a deeper understanding of heterogeneous polygenic CVDs, better prognostic guidance, and, ultimately, greater personalized medicine. Advances will likely be achieved through increasingly frequent and robust genomic characterization of patients, as well the integration of genomic data with other clinical data, such as cardiac imaging, coronary angiography, and clinical biomarkers. This review discusses the current opportunities and limitations of genomics; provides a brief overview of AI; and identifies the current applications, limitations, and future directions of AI in genomics.
Krittanawong et al. (Mon,) conducted a review in Polygenic cardiovascular diseases. Artificial intelligence and next generation sequencing was evaluated. Combining artificial intelligence with next-generation sequencing technologies offers unprecedented possibilities for dynamic genomic analyses to better understand polygenic cardiovascular diseases.